1. Home
  2. VBNK vs DCTH Comparison

VBNK vs DCTH Comparison

Compare VBNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VersaBank

VBNK

VersaBank

N/A

Current Price

$15.05

Market Cap

374.8M

Sector

Finance

ML Signal

N/A

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.91

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VBNK
DCTH
Founded
1980
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Commercial Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
374.8M
350.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VBNK
DCTH
Price
$15.05
$9.91
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$13.00
$22.60
AVG Volume (30 Days)
51.5K
484.9K
Earning Date
12-10-2025
11-04-2025
Dividend Yield
0.48%
N/A
EPS Growth
N/A
N/A
EPS
0.64
0.03
Revenue
$85,792,576.00
$79,603,000.00
Revenue This Year
$37.01
$131.69
Revenue Next Year
$30.71
$39.22
P/E Ratio
$23.58
$288.36
Revenue Growth
7.44
251.54
52 Week Low
$8.51
$8.12
52 Week High
$15.57
$18.23

Technical Indicators

Market Signals
Indicator
VBNK
DCTH
Relative Strength Index (RSI) 82.33 50.27
Support Level $14.86 $9.98
Resistance Level $15.44 $10.37
Average True Range (ATR) 0.35 0.35
MACD -0.01 -0.02
Stochastic Oscillator 60.27 24.48

Price Performance

Historical Comparison
VBNK
DCTH

About VBNK VersaBank

VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: